Description
A selective p38α/β MAPK inhibitor (pKi = 8.1 and 7.6, respectively); inhibits TNF-α production (IC50 = 31 nM); improves survival and blood pressure in hypertensive rats; did not proceed past Phase II clinical trials,,
Formal name: 6-[5-[(cyclopropylamino)carbonyl]-3-fluoro-2-methylphenyl]-N-(2,2-dimethylpropyl)-3-pyridinecarboxamide
Synonyms: GSK-AHAB|SB 856553
Molecular weight: 383.5
CAS: 585543-15-3
Purity: ≥98%
Formulation: A crystalline solid
Product Type|Biochemicals|Kinase Inhibitors|p38 MAPK||Product Type|Biochemicals|Small Molecule Inhibitors|Kinases||Research Area|Cardiovascular System|Cardiovascular Diseases|Hypertension||Research Area|Cardiovascular System|Cardiovascular Diseases|Myocardial Infarction||Research Area|Cardiovascular System|Heart||Research Area|Cardiovascular System|Lipids & Lipoproteins|Lipoproteins||Research Area|Cell Biology|Cell Signaling|p38 MAPK Signaling||Research Area|Immunology & Inflammation|Innate Immunity